Biogen Inc
(BSP:BIIB34)
R$
169.49
1.36 (0.81%)
Market Cap: 149.37 Bil
Enterprise Value: 178.06 Bil
PE Ratio: 15.80
PB Ratio: 1.56
GF Score: 75/100 Biogen Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024 / 07:15PM GMT
Release Date Price:
R$207.9
(+1.32%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
So good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat today with Chris Viehbacher, who joined Biogen as CEO, I guess, a little bit over a year ago. So Chris, happy New Year. Thanks for joining us.
Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director
Happy New year to you too, Chris.
Questions & Answers
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
Yes. So I think we were talking before. About a year ago, we were sitting in these same 2 seats. You had just come on as CEO. So I would love to start the conversation with just your reflections on how the last year has gone, anything that surprised you at a positive or negative in the CEO seat? And we'll kick off from there.
Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director
Well, thanks, Chris. Yes,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot